13.58.232.94
dgid:
enl:
npi:0
-Advertisement-
Home Michael Kazim, MD discusses AAO Presentation

Thyroid Eye Disease

Michael Kazim, MD discusses AAO Presentation

Read More
By rd360stg
Case Series: TED reactivation after COVID-19 vaccination
By rd360stg
Teprotumumab adherence rates are high in patients with TED
By rd360stg
Does smoking decrease effectiveness of teprotumumab in thyroid eye disease?
By rd360stg
How did pandemic-related teprotumumab treatment delays impact outcomes?
-Advertisement-
-Advertisement-
-Advertisement-
By rd360stg
Teprotumumab retreatment beneficial for TED patients with insufficient initial response
By rd360stg
Statins improves Graves’ orbitopathy outcomes in patients with active eye disease
By rd360stg
Lasting quality of life improvements seen after orbital decompression in patients with TED
By rd360stg
TED biomarkers provide potential information for therapeutic targets
-Advertisement-
-Advertisement-
-Advertisement-
By rd360stg
Horizon Therapeutics to resupply market with Tepezza for the treatment of thyroid eye disease (TED) beginning in April
By rd360stg
Positive Phase 2a Study Results Announced for Thyroid Eye Disease Treatment
-Advertisement-
-Advertisement-
Videos
All
Michael Kazim, MD discusses AAO Presentation
13 Dec, 2021

-Advertisement-
-Advertisement-

Contact Info

Grandin Library Building
Six Leigh Street
Clinton, New Jersey 08809

+908-505-8899
[email protected]

Social Links

© 2024 Ophthalmology 360® is a trademark of International Healthcare Media, LLC. All rights Reserved
-Advertisement-
-Advertisement-